Clopidogrel and the reduced-function CYP2C19 genetic variant: A limited piece of the overall therapeutic puzzle

JAMA

Volumn 304, Issue 16, 2010, Pages 1839-1840

  Fuster, Valentin ^a,b   Sweeny, Joseph M ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; GLYCOPROTEIN P; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; ALLELE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY STENT; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG ELUTING STENT; DRUG RESPONSE; DYSLIPIDEMIA; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; STROKE; TREATMENT REFUSAL; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; GENETICS; PATIENT SELECTION; PHARMACOGENETICS; RISK; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 CYP2C19; GENOTYPE; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; RISK; STENTS; TICLOPIDINE;

EID: 78049348037     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1566     Document Type: Editorial

References (16)

1. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention. Lancet. 2001;358(9281):527-533.
2. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246-251. (Pubitemid 40094733)
3. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug 'resistance', part 1: mechanisms and clinical measurements. Nat Rev Cardiol. 2009;6(4):273-282.
4. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244-2247. (Pubitemid 44497506)
5. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
6. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction. Lancet. 2009;373 (9660):309-317.
7. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
8. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
9. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning." Circulation. 2010;122(5):537-557.
10. US Food and Drug Administration. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http//www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed September 15, 2010.
11. Mega JL, Simon T, Collet J-P, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA. 2010;304(16):1821-1830.
12. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
13. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial [published online August 27, 2010]. Lancet. 2010.
14. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes [published online August 27, 2010]. Lancet.
15. Pare G, Mehta S, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment [published online August 29, 2010]. N Engl J Med. doi:10.1056/NEJMoa1008410.
16. Hulot JS, Fuster V. Antiplatelet therapy: Personalized medicine for clopidogrel resistance? Nat Rev Cardiol. 2009;6(5):334-336.